The Square Peg Problem: Why FDA’s Bayesian–Frequentist Truce Still Hurts
In January 2026, the FDA released updated guidance on the use of Bayesian methods in clinical trials. The document does not read like a manifesto. It reads like an attempt to reconcile competing statistical cultures under real regulatory constraints. On its surface, it is pragmatic and flexible, welcoming Bayesian designs